Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
77 hedge funds and large institutions have $70M invested in Adverum Biotechnologies in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 27 reducing their positions, and 29 closing their positions.
14,515% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $13K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.55% less ownership
Funds ownership: 6.44% → 5.9% (-0.55%)
16% less funds holding
Funds holding: 92 → 77 (-15)
18% less capital invested
Capital invested by funds: $85.9M → $70M (-$15.9M)
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
59% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.35M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.81M |
| 3 |
Millennium Management
New York
|
+$1.09M |
| 4 |
NM
Newtyn Management
New York
|
+$1.08M |
| 5 |
Renaissance Technologies
New York
|
+$730K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$9.11M |
| 2 |
BlackRock
New York
|
-$4.18M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.49M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.55M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$883K |
ADVM Hedge Fund Activity: Q2 2022 in Review
77 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q2 2022, worth a combined $70M — down 18% from $85.9M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ADVM and 16 opened new positions — a net loss of 13 holders — while 27 trimmed existing stakes and 11 added.
The largest buyer was Morgan Stanley, adding an estimated $7.35M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $9.11M sold.
- 77 institutional investors held Adverum Biotechnologies (ADVM) as of Q2 2022, down from 92 in Q1 2022.
- Funds reported $70M of Adverum Biotechnologies stock for Q2 2022, down 18% quarter-over-quarter.
- 16 funds opened new Adverum Biotechnologies positions in Q2 2022 and 29 closed out, a net change of -13 holders.
- The largest Adverum Biotechnologies buyer in Q2 2022 was Morgan Stanley, an estimated $7.35M added.
- The largest Adverum Biotechnologies seller in Q2 2022 was Avoro Capital Advisors, an estimated $9.11M sold.
Based on aggregated 13F filings for Q2 2022.